8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 3, 2017

SHIRE PLC

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands	0-29630	98-0601486
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

5 Riverwalk, Citywest Business Campus, Dublin

24, Republic of Ireland
(Address of principal executive offices)

Registrant’s telephone number, including area code: +353 1 429 7700

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The Board of Directors of Shire plc (“Shire”) announced on January 3, 2017 that Ian Clark will join the Board of Directors as a non-executive director with effect from January 3, 2017. No determination has been made as to any board committees on which Mr. Clark may serve.

Mr. Clark will receive compensation in accordance with Shire’s Remuneration Policy for non-executive directors. No shares will be granted to Mr. Clark on his appointment as a director, but 25% of the fees payable to him under the Remuneration Policy will be payable in the form of shares.

Shire has issued a press release attached as Exhibit 99.1 which is incorporated by reference herein.

Item 8.01. Other Events

Shire has issued a press release attached as Exhibit 99.2 which is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibits are filed herewith:

99.1       Press Release dated January 3, 2017

99.2       Press Release dated January 4, 2017

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Shire plc
By:	/s/ W R Mordan
	Name:	Bill Mordan
	Title:	Company Secretary

Date: January 4, 2017

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated January 3, 2017
99.2	Press Release dated January 4, 2017

EX-99.1

Exhibit 99.1

Press Release
www.shire.com

Directorate change

Appointment of Ian Clark as Non-Executive Director

January 3, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (“Shire”’ / the “Company”) announces the appointment of Ian Clark as a Non-Executive Director of the Company with effect from the date of this announcement.

Mr. Clark served as Chief Executive Officer and Director of Genentech Inc (part of the Roche Group) and Head of North American Commercial Operations for Roche until December 31, 2016, having held several senior strategy, operations and commercially focused roles since joining Genentech in 2003. Prior to this Mr. Clark held various senior operational, sales and marketing roles in other pharmaceutical and healthcare companies. He is currently appointed as a Non-Executive Director of TerraVia Holdings Inc. where he serves as Chairman of the Compensation Committee and as a member of the Nominating and Corporate Governance Committee.

Susan Kilsby, Shire’s Chairman, commented: “We are very pleased to announce Ian’s appointment at this important time; his in-depth knowledge of the biotechnology sector and breadth of operational experience stand to serve Shire well as we look forward to growing our business and addressing unmet patient needs world-wide.”

Mr. Clark added: “Shire has demonstrated commitment to being the global leader in rare diseases and to delivering value to its patients, physicians, shareholders and other stakeholders. I look forward to working with Susan and the rest of the Board in pursuing a successful future for the Company.”

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations
Ian Karp	ikarp@shire.com	+1 781 482 9018
Robert Coates	rcoates@shire.com	+44 1256 894874
Media
Lisa Adler	lisa.adler@shire.com	+1 617 588 8607
Debbi Ford	debbi.ford@shire.com	+1 617 949 9083

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

NOTES TO EDITORS

No further information is required to be disclosed pursuant to 9.6.13R of the UK Listing Rules.

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com

2 

EX-99.2

Exhibit 99.2

Press Release
www.shire.com

Director Declaration

January 4, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that Ian Clark, Non-Executive Director of the Company, was appointed to the Boards of Directors of Agios Pharmaceuticals, Inc. and Corvus Pharmaceuticals, Inc. on January 3, 2017.

This notification is to satisfy the Company’s obligations under LR 9.6.14R of the UK Listing Rules.

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations
Ian Karp	ikarp@shire.com	+1 781 482 9018
Robert Coates	rcoates@shire.com	+44 1256 894874
Media
Lisa Adler	lisa.adler@shire.com	+1 617 588 8607
Debbi Ford	debbi.ford@shire.com	+1 617 949 9083

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX